{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:10:49Z","timestamp":1792714249041,"version":"4.5.0"},"reference-count":190,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,9,3]],"date-time":"2019-09-03T00:00:00Z","timestamp":1567468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,9,3]],"date-time":"2019-09-03T00:00:00Z","timestamp":1567468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s00415-019-09498-4","type":"journal-article","created":{"date-parts":[[2019,9,3]],"date-time":"2019-09-03T13:52:20Z","timestamp":1567518740000},"page":"1643-1664","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Role of complement and potential of complement inhibitors in myasthenia gravis and neuromyelitis optica spectrum disorders: a brief review"],"prefix":"10.1007","volume":"268","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5699-9595","authenticated-orcid":false,"given":"Jayne L.","family":"Chamberlain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saif","family":"Huda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel H.","family":"Whittam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo","family":"Matiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. Paul","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anu","family":"Jacob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,9,3]]},"reference":[{"key":"9498_CR1","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1002\/eji.1830241042","volume":"24","author":"OH Brekke","year":"1994","unstructured":"Brekke OH, Michaelsen TE, Aase A et al (1994) Human IgG isotype-specific amino acid residues affecting complement-mediated cell lysis and phagocytosis. Eur J Immunol 24:2542\u20132547. https:\/\/doi.org\/10.1002\/eji.1830241042","journal-title":"Eur J Immunol"},{"key":"9498_CR2","doi-asserted-by":"crossref","first-page":"5633","DOI":"10.1016\/S0021-9258(20)79774-7","volume":"249","author":"JG Petersen","year":"1974","unstructured":"Petersen JG, Dorrington KJ (1974) An in vitro system for studying the kinetics of interchain disulfide bond formation in immunoglobulin G. J Biol Chem 249:5633\u20135641","journal-title":"J Biol Chem"},{"key":"9498_CR3","doi-asserted-by":"crossref","first-page":"3566","DOI":"10.4049\/jimmunol.137.11.3566","volume":"137","author":"JS van der Zee","year":"1986","unstructured":"van der Zee JS, van Swieten P, Aalberse RC (1986) Serologic aspects of IgG4 antibodies. II. IgG4 antibodies form small, nonprecipitating immune complexes due to functional monovalency. J Immunol 137:3566\u20133571","journal-title":"J Immunol"},{"key":"9498_CR4","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/0161-5890(93)90432-B","volume":"30","author":"S Angal","year":"1993","unstructured":"Angal S, King DJ, Bodmer MW et al (1993) A single amino acid substitution abolishes the heterogeneity of chimeric mouse\/human (IgG4) antibody. Mol Immunol 30:105\u2013108","journal-title":"Mol Immunol"},{"key":"9498_CR5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0161-5890(01)00050-5","volume":"38","author":"J Schuurman","year":"2001","unstructured":"Schuurman J, Perdok GJ, Gorter AD, Aalberse RC (2001) The inter-heavy chain disulfide bonds of IgG4 are in equilibrium with intra-chain disulfide bonds. Mol Immunol 38:1\u20138","journal-title":"Mol Immunol"},{"key":"9498_CR6","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1126\/science.1144603","volume":"317","author":"Kolfschoten M van der Neut","year":"2007","unstructured":"van der Neut Kolfschoten M, Schuurman J, Losen M et al (2007) Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science 317:1554\u20131557. https:\/\/doi.org\/10.1126\/science.1144603","journal-title":"Science"},{"key":"9498_CR7","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1038\/nrd4657","volume":"14","author":"BP Morgan","year":"2015","unstructured":"Morgan BP, Harris CL (2015) Complement, a target for therapy in inflammatory and degenerative diseases. Nat Rev Drug Discov 14:857\u2013877. https:\/\/doi.org\/10.1038\/nrd4657","journal-title":"Nat Rev Drug Discov"},{"key":"9498_CR8","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.1182\/blood-2014-02-522128","volume":"124","author":"RA Brodsky","year":"2014","unstructured":"Brodsky RA (2014) Paroxysmal nocturnal hemoglobinuria. Blood 124:2804\u20132811. https:\/\/doi.org\/10.1182\/blood-2014-02-522128","journal-title":"Blood"},{"key":"9498_CR9","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1046\/J.1365-2249.2000.01129.X","volume":"119","author":"RM Goodfellow","year":"2000","unstructured":"Goodfellow RM, Williams AS, Levin JL et al (2000) Soluble complement receptor one (sCR9) inhibits the development and progression of rat collagen-induced arthritis. Clin Exp Immunol 119:210\u2013216. https:\/\/doi.org\/10.1046\/J.1365-2249.2000.01129.X","journal-title":"Clin Exp Immunol"},{"key":"9498_CR10","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1046\/J.1365-2567.1999.00742.X","volume":"97","author":"J Oberholzer","year":"1999","unstructured":"Oberholzer J, Yu D, Triponez F et al (1999) Decomplementation with cobra venom factor prolongs survival of xenografted islets in a rat to mouse model. Immunology 97:173\u2013180. https:\/\/doi.org\/10.1046\/J.1365-2567.1999.00742.X","journal-title":"Immunology"},{"key":"9498_CR11","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1038\/nbt1344","volume":"25","author":"RP Rother","year":"2007","unstructured":"Rother RP, Rollins SA, Mojcik CF et al (2007) Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol 25:1256\u20131264. https:\/\/doi.org\/10.1038\/nbt1344","journal-title":"Nat Biotechnol"},{"key":"9498_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(13)70076-0","author":"SJ Pittock","year":"2013","unstructured":"Pittock SJ, Lennon VA, McKeon A et al (2013) Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol. https:\/\/doi.org\/10.1016\/S1474-4422(13)70076-0","journal-title":"Lancet Neurol"},{"key":"9498_CR13","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1002\/mus.23839","volume":"48","author":"JF Howard","year":"2013","unstructured":"Howard JF, Barohn RJ, Cutter GR et al (2013) A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis. Muscle Nerve 48:76\u201384. https:\/\/doi.org\/10.1002\/mus.23839","journal-title":"Muscle Nerve"},{"key":"9498_CR14","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1111\/j.1600-6143.2011.03757.x","volume":"11","author":"MD Stegall","year":"2011","unstructured":"Stegall MD, Diwan T, Raghavaiah S et al (2011) Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant 11:2405\u20132413. https:\/\/doi.org\/10.1111\/j.1600-6143.2011.03757.x","journal-title":"Am J Transplant"},{"key":"9498_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1212\/NXI.0000000000000005","volume":"1","author":"M Levy","year":"2014","unstructured":"Levy M, Mealy MA (2014) Purified human C1-esterase inhibitor is safe in acute relapses of neuromyelitis optica. Neurol Neuroimmunol NeuroInflammation 1:1\u20135. https:\/\/doi.org\/10.1212\/NXI.0000000000000005","journal-title":"Neurol Neuroimmunol NeuroInflammation"},{"key":"9498_CR16","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.4049\/jimmunol.1600091","volume":"197","author":"M Kalbitz","year":"2016","unstructured":"Kalbitz M, Fattahi F, Herron TJ et al (2016) Complement destabilizes cardiomyocyte function in vivo after polymicrobial sepsis and in vitro. J Immunol 197:2353\u20132361. https:\/\/doi.org\/10.4049\/jimmunol.1600091","journal-title":"J Immunol"},{"key":"9498_CR17","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.molimm.2014.06.030","volume":"61","author":"AS Grumach","year":"2014","unstructured":"Grumach AS, Kirschfink M (2014) Are complement deficiencies really rare? Overview on prevalence, clinical importance and modern diagnostic approach. Mol Immunol 61:110\u2013117","journal-title":"Mol Immunol"},{"key":"9498_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2013.11.023","author":"D Westra","year":"2014","unstructured":"Westra D, Kurvers RAJ, Van den Heuvel LP et al (2014) Compound heterozygous mutations in the C6 gene of a child with recurrent infections. Mol Immunol. https:\/\/doi.org\/10.1016\/j.molimm.2013.11.023","journal-title":"Mol Immunol"},{"key":"9498_CR19","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2011.04525.x","author":"A Orren","year":"2012","unstructured":"Orren A, Owen EP, Henderson HE et al (2012) Complete deficiency of the sixth complement component (C6Q0), susceptibility to Neisseria meningitidis infections and analysis of the frequencies of C6Q0 gene defects in South Africans. Clin Exp Immunol. https:\/\/doi.org\/10.1111\/j.1365-2249.2011.04525.x","journal-title":"Clin Exp Immunol"},{"key":"9498_CR20","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1002\/art.39589","volume":"68","author":"J Yih Chen","year":"2016","unstructured":"Yih Chen J, Ling WuY, Yin Mok M et al (2016) Effects of complement C4 gene copy number variations, size dichotomy, and C4A deficiency on genetic risk and clinical presentation of systemic lupus erythematosus in East Asian populations. Arthritis Rheumatol 68:1442\u20131453. https:\/\/doi.org\/10.1002\/art.39589","journal-title":"Arthritis Rheumatol"},{"key":"9498_CR21","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.4049\/jimmunol.169.4.2126","volume":"169","author":"SD Fleming","year":"2002","unstructured":"Fleming SD, Shea-Donohue T, Guthridge JM et al (2002) Mice deficient in complement receptors 1 and 2 lack a tissue injury-inducing subset of the natural antibody repertoire. J Immunol 169:2126\u20132133","journal-title":"J Immunol"},{"key":"9498_CR22","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/cr.2009.139","volume":"20","author":"JR Dunkelberger","year":"2009","unstructured":"Dunkelberger JR, Song W-C (2009) Complement in host immunity 34 complement and its role in innate and adaptive immune responses. Cell Res 20:34\u20135034. https:\/\/doi.org\/10.1038\/cr.2009.139","journal-title":"Cell Res"},{"key":"9498_CR23","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1073\/pnas.1316877111","volume":"111","author":"L Baudino","year":"2014","unstructured":"Baudino L, Sardini A, Ruseva MM et al (2014) C3 opsonization regulates endocytic handling of apoptotic cells resulting in enhanced T-cell responses to cargo-derived antigens. Proc Natl Acad Sci 111:1503\u20131508. https:\/\/doi.org\/10.1073\/pnas.1316877111","journal-title":"Proc Natl Acad Sci"},{"key":"9498_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2005.04.006","author":"C Wagner","year":"2006","unstructured":"Wagner C, Ochmann C, Schoels M et al (2006) The complement receptor 1, CR1 (CD35), mediates inhibitory signals in human T-lymphocytes. Mol Immunol. https:\/\/doi.org\/10.1016\/j.molimm.2005.04.006","journal-title":"Mol Immunol"},{"key":"9498_CR25","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","volume":"364","author":"VA Lennon","year":"2004","unstructured":"Lennon VA, Wingerchuk DM, Kryzer TJ et al (2004) A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet (London, England) 364:2106\u20132112. https:\/\/doi.org\/10.1016\/S0140-6736(04)17551-X","journal-title":"Lancet (London, England)"},{"key":"9498_CR26","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1084\/jem.20050304","volume":"202","author":"VA Lennon","year":"2005","unstructured":"Lennon VA, Kryzer TJ, Pittock SJ et al (2005) IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 202:473\u2013477. https:\/\/doi.org\/10.1084\/jem.20050304","journal-title":"J Exp Med"},{"key":"9498_CR27","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","volume":"85","author":"DM Wingerchuk","year":"2015","unstructured":"Wingerchuk DM, Banwell B, Bennett JL et al (2015) International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85:177\u2013189. https:\/\/doi.org\/10.1212\/WNL.0000000000001729","journal-title":"Neurology"},{"key":"9498_CR28","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1212\/01.wnl.0000183151.19351.82","volume":"65","author":"T Misu","year":"2005","unstructured":"Misu T, Fujihara K, Nakashima I et al (2005) Intractable hiccup and nausea with periaqueductal lesions in neuromyelitis optica. Neurology 65:1479\u20131482. https:\/\/doi.org\/10.1212\/01.wnl.0000183151.19351.82","journal-title":"Neurology"},{"key":"9498_CR29","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1002\/ana.22121","volume":"68","author":"M Apiwattanakul","year":"2010","unstructured":"Apiwattanakul M, Popescu BF, Matiello M et al (2010) Intractable vomiting as the initial presentation of neuromyelitis optica. Ann Neurol 68:757\u2013761. https:\/\/doi.org\/10.1002\/ana.22121","journal-title":"Ann Neurol"},{"key":"9498_CR30","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1191\/1352458505ms1200cr","volume":"11","author":"AY Poppe","year":"2005","unstructured":"Poppe AY, Lapierre Y, Melan\u00e7on D et al (2005) Neuromyelitis optica with hypothalamic involvement. Mult Scler 11:617\u2013621. https:\/\/doi.org\/10.1191\/1352458505ms1200cr","journal-title":"Mult Scler"},{"key":"9498_CR31","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s00415-014-7537-y","volume":"262","author":"S Pu","year":"2015","unstructured":"Pu S, Long Y, Yang N et al (2015) Syndrome of inappropriate antidiuretic hormone secretion in patients with aquaporin-4 antibody. J Neurol 262:101\u2013107. https:\/\/doi.org\/10.1007\/s00415-014-7537-y","journal-title":"J Neurol"},{"key":"9498_CR32","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s00415-009-0139-4","volume":"256","author":"T Baba","year":"2009","unstructured":"Baba T, Nakashima I, Kanbayashi T et al (2009) Narcolepsy as an initial manifestation of neuromyelitis optica with anti-aquaporin-4 antibody. J Neurol 256:287\u2013288. https:\/\/doi.org\/10.1007\/s00415-009-0139-4","journal-title":"J Neurol"},{"key":"9498_CR33","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1212\/WNL.53.5.1107","volume":"53","author":"DM Wingerchuk","year":"1999","unstructured":"Wingerchuk DM, Hogancamp WF, O\u2019Brien PC, Weinshenker BG (1999) The clinical course of neuromyelitis optica (Devic\u2019s syndrome). Neurology 53:1107\u20131114","journal-title":"Neurology"},{"key":"9498_CR34","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/bpa.12099","volume":"24","author":"CF Lucchinetti","year":"2014","unstructured":"Lucchinetti CF, Guo Y, Popescu BFG et al (2014) The pathology of an autoimmune astrocytopathy: lessons learned from neuromyelitis optica. Brain Pathol 24:83\u201397. https:\/\/doi.org\/10.1111\/bpa.12099","journal-title":"Brain Pathol"},{"key":"9498_CR35","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/nyas.12794","volume":"1366","author":"SJ Pittock","year":"2016","unstructured":"Pittock SJ, Lucchinetti CF (2016) Neuromyelitis optica and the evolving spectrum of autoimmune aquaporin-4 channelopathies: a decade later. Ann N Y Acad Sci 1366:20\u201339. https:\/\/doi.org\/10.1111\/nyas.12794","journal-title":"Ann N Y Acad Sci"},{"key":"9498_CR36","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1073\/pnas.1109980108","volume":"109","author":"SR Hinson","year":"2012","unstructured":"Hinson SR, Romero MF, Popescu BFG et al (2012) Molecular outcomes of neuromyelitis optica (NMO)-IgG binding to aquaporin-4 in astrocytes. Proc Natl Acad Sci USA 109:1245\u20131250. https:\/\/doi.org\/10.1073\/pnas.1109980108","journal-title":"Proc Natl Acad Sci USA"},{"key":"9498_CR37","doi-asserted-by":"publisher","first-page":"e121","DOI":"10.1212\/NXI.0000000000000121","volume":"2","author":"J Kitley","year":"2015","unstructured":"Kitley J, Woodhall M, Leite MI et al (2015) Aquaporin-4 antibody isoform binding specificities do not explain clinical variations in NMO. Neurol Neuroimmunol neuroinflammation 2:e121. https:\/\/doi.org\/10.1212\/NXI.0000000000000121","journal-title":"Neurol Neuroimmunol neuroinflammation"},{"key":"9498_CR38","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1073\/pnas.1616998114","volume":"114","author":"SA Mortensen","year":"2017","unstructured":"Mortensen SA, Sander B, Jensen RK et al (2017) Structure and activation of C1, the complex initiating the classical pathway of the complement cascade. Proc Natl Acad Sci 114:986\u2013991. https:\/\/doi.org\/10.1073\/pnas.1616998114","journal-title":"Proc Natl Acad Sci"},{"key":"9498_CR39","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/1742-2094-8-146","volume":"8","author":"K Lehmann-Horn","year":"2011","unstructured":"Lehmann-Horn K, Schleich E, Hertzenberg D et al (2011) Anti-CD20 B-cell depletion enhances monocyte reactivity in neuroimmunological disorders. J Neuroinflammation 8:146. https:\/\/doi.org\/10.1186\/1742-2094-8-146","journal-title":"J Neuroinflammation"},{"key":"9498_CR40","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/1742-2094-8-184","volume":"8","author":"S Mader","year":"2011","unstructured":"Mader S, Gredler V, Schanda K et al (2011) Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders. J Neuroinflammation 8:184. https:\/\/doi.org\/10.1186\/1742-2094-8-184","journal-title":"J Neuroinflammation"},{"key":"9498_CR41","doi-asserted-by":"publisher","first-page":"e62","DOI":"10.1212\/NXI.0000000000000062","volume":"2","author":"SS Zamvil","year":"2015","unstructured":"Zamvil SS, Slavin AJ (2015) Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder? Neurol Neuroimmunol neuroinflammation 2:e62. https:\/\/doi.org\/10.1212\/NXI.0000000000000062","journal-title":"Neurol Neuroimmunol neuroinflammation"},{"key":"9498_CR42","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1001\/archneurol.2009.188","volume":"66","author":"SR Hinson","year":"2009","unstructured":"Hinson SR, McKeon A, Fryer JP et al (2009) Prediction of neuromyelitis optica attack severity by quantitation of complement-mediated injury to aquaporin-4\u2014expressing cells. Arch Neurol 66:1164\u20131167. https:\/\/doi.org\/10.1001\/archneurol.2009.188","journal-title":"Arch Neurol"},{"key":"9498_CR43","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M112.344325","author":"PW Phuan","year":"2012","unstructured":"Phuan PW, Ratelade J, Rossi A et al (2012) Complement-dependent cytotoxicity in neuromyelitis optica requires aquaporin-4 protein assembly in orthogonal arrays. J Biol Chem. https:\/\/doi.org\/10.1074\/jbc.M112.344325","journal-title":"J Biol Chem"},{"key":"9498_CR44","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.bbrep.2016.05.012","volume":"7","author":"S Nishiyama","year":"2016","unstructured":"Nishiyama S, Misu T, Nuriya M et al (2016) Complement-dependent and -independent aquaporin 4-antibody-mediated cytotoxicity in human astrocytes: pathogenetic implications in neuromyelitis optica. Biochem Biophys Reports 7:45\u201351. https:\/\/doi.org\/10.1016\/j.bbrep.2016.05.012","journal-title":"Biochem Biophys Reports"},{"key":"9498_CR45","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/2051-5960-2-53","volume":"2","author":"G Ingram","year":"2014","unstructured":"Ingram G, Loveless S, Howell OW et al (2014) Complement activation in multiple sclerosis plaques: an immunohistochemical analysis. Acta Neuropathol Commun 2:53. https:\/\/doi.org\/10.1186\/2051-5960-2-53","journal-title":"Acta Neuropathol Commun"},{"key":"9498_CR46","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1093\/brain\/awf151","volume":"125","author":"CF Lucchinetti","year":"2002","unstructured":"Lucchinetti CF, Mandler RN, Mcgavern D et al (2002) A role for humoral mechanisms in the pathogenesis of Devic\u2019s neuromyelitis optica. Brain 125:1450\u20131461","journal-title":"Brain"},{"key":"9498_CR47","doi-asserted-by":"publisher","DOI":"10.1177\/1352458516669002","author":"S Hakobyan","year":"2016","unstructured":"Hakobyan S, Luppe S, Evans DR et al (2016) Plasma complement biomarkers distinguish multiple sclerosis and neuromyelitis optica spectrum disorder. Mult Scler J. https:\/\/doi.org\/10.1177\/1352458516669002","journal-title":"Mult Scler J"},{"key":"9498_CR48","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/0006-8993(71)90052-7","volume":"28","author":"CE Lumsden","year":"1971","unstructured":"Lumsden CE (1971) The immunogenesis of the multiple sclerosis plaque. Brain Res 28:365\u2013390","journal-title":"Brain Res"},{"key":"9498_CR49","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1111\/j.1365-2990.1989.tb01231.x","volume":"15","author":"DAS Compston","year":"1989","unstructured":"Compston DAS, Morgan BP, Campbell AK et al (1989) Immunocytochemical localization of the terminal complement complex in multiple sclerosis. Neuropathol Appl Neurobiol 15:307\u2013316. https:\/\/doi.org\/10.1111\/j.1365-2990.1989.tb01231.x","journal-title":"Neuropathol Appl Neurobiol"},{"key":"9498_CR50","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.jneuroim.2012.09.002","volume":"254","author":"H Kuroda","year":"2013","unstructured":"Kuroda H, Fujihara K, Takano R et al (2013) Increase of complement fragment C5a in cerebrospinal fluid during exacerbation of neuromyelitis optica. J Neuroimmunol 254:178\u2013182. https:\/\/doi.org\/10.1016\/j.jneuroim.2012.09.002","journal-title":"J Neuroimmunol"},{"key":"9498_CR51","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.jneuroim.2014.07.001","volume":"274","author":"P Nytrova","year":"2014","unstructured":"Nytrova P, Potlukova E, Kemlink D et al (2014) Complement activation in patients with neuromyelitis optica. J Neuroimmunol 274:185\u2013191. https:\/\/doi.org\/10.1016\/j.jneuroim.2014.07.001","journal-title":"J Neuroimmunol"},{"key":"9498_CR52","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.jneuroim.2012.03.020","volume":"247","author":"MC S\u00e1daba","year":"2012","unstructured":"S\u00e1daba MC, Tzartos J, Pa\u00edno C et al (2012) Axonal and oligodendrocyte-localized IgM and IgG deposits in MS lesions. J Neuroimmunol 247:86\u201394. https:\/\/doi.org\/10.1016\/j.jneuroim.2012.03.020","journal-title":"J Neuroimmunol"},{"key":"9498_CR53","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1001\/archneur.65.7.913","volume":"65","author":"P Waters","year":"2008","unstructured":"Waters P, Jarius S, Littleton E et al (2008) Aquaporin-4 antibodies in neuromyelitis optica and longitudinally extensive transverse myelitis. Arch Neurol 65:913\u2013919. https:\/\/doi.org\/10.1001\/archneur.65.7.913","journal-title":"Arch Neurol"},{"key":"9498_CR54","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/jnen\/64.2.147","volume":"64","author":"BP Brink","year":"2005","unstructured":"Brink BP, Veerhuis R, Breij ECW et al (2005) The pathology of multiple sclerosis is location-dependent: no significant complement activation is detected in purely cortical lesions. J Neuropathol Exp Neurol 64:147\u2013155","journal-title":"J Neuropathol Exp Neurol"},{"key":"9498_CR55","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/jca.2920100402","volume":"10","author":"EC Vamvakas","year":"1995","unstructured":"Vamvakas EC, Pineda AA, Weinshenker BG (1995) Meta-analysis of clinical studies of the efficacy of plasma exchange in the treatment of chronic progressive multiple sclerosis. J Clin Apher 10:163\u2013170","journal-title":"J Clin Apher"},{"key":"9498_CR56","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1093\/brain\/112.4.895","volume":"112","author":"C Linington","year":"1989","unstructured":"Linington C, Morgan BP, Scolding NJ et al (1989) The role of complement in the pathogenesis of experimental allergic encephalomyelitis. Brain 112:895\u2013911","journal-title":"Brain"},{"key":"9498_CR57","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3109\/00207459708986406","volume":"92","author":"FJ Vriesendorp","year":"1997","unstructured":"Vriesendorp FJ, Flynn RE, Pappolla MA, Koski CL (1997) Soluble complement receptor 1 (sCR59) is not as effective as cobra venom factor in the treatment of experimental allergic neuritis. Int J Neurosci 92:287\u2013298","journal-title":"Int J Neurosci"},{"key":"9498_CR58","doi-asserted-by":"publisher","first-page":"458","DOI":"10.4049\/JIMMUNOL.168.1.458","volume":"168","author":"RJ Mead","year":"2002","unstructured":"Mead RJ, Singhrao SK, Neal JW et al (2002) The membrane attack complex of complement causes severe demyelination associated with acute axonal injury. J Immunol 168:458\u2013465. https:\/\/doi.org\/10.4049\/JIMMUNOL.168.1.458","journal-title":"J Immunol"},{"key":"9498_CR59","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/S0002-9440(10)63466-9","volume":"163","author":"SH Weerth","year":"2003","unstructured":"Weerth SH, Rus H, Shin ML, Raine CS (2003) Complement C5 in experimental autoimmune encephalomyelitis (EAE) facilitates remyelination and prevents gliosis. Am J Pathol 163:1069\u20131080. https:\/\/doi.org\/10.1016\/S0002-9440(10)63466-9","journal-title":"Am J Pathol"},{"key":"9498_CR60","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1002\/ana.21837","volume":"66","author":"M Bradl","year":"2009","unstructured":"Bradl M, Misu T, Takahashi T et al (2009) Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann Neurol 66:630\u2013643. https:\/\/doi.org\/10.1002\/ana.21837","journal-title":"Ann Neurol"},{"key":"9498_CR61","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1093\/brain\/awp309","volume":"133","author":"S Saadoun","year":"2010","unstructured":"Saadoun S, Waters P, Bell BA et al (2010) Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain 133:349\u2013361. https:\/\/doi.org\/10.1093\/brain\/awp309","journal-title":"Brain"},{"key":"9498_CR62","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1177\/1352458508099139","volume":"15","author":"H Doi","year":"2009","unstructured":"Doi H, Matsushita T, Isobe N et al (2009) Hypercomplementemia at relapse in patients with anti-aquaporin-4 antibody. Mult Scler 15:304\u2013310. https:\/\/doi.org\/10.1177\/1352458508099139","journal-title":"Mult Scler"},{"key":"9498_CR63","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.neuroscience.2009.08.032","volume":"168","author":"SR Hinson","year":"2010","unstructured":"Hinson SR, McKeon A, Lennon VA (2010) Neurological autoimmunity targeting aquaporin-4. Neuroscience 168:1009\u20131018","journal-title":"Neuroscience"},{"key":"9498_CR64","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jns.2015.05.034","volume":"355","author":"WL De Carvalho Jennings Pereira","year":"2015","unstructured":"De Carvalho Jennings Pereira WL, Reiche EMV, Kallaur AP, Kaimen-Maciel DR (2015) Epidemiological, clinical, and immunological characteristics of neuromyelitis optica: a review. J Neurol Sci 355:7\u201317","journal-title":"J Neurol Sci"},{"key":"9498_CR65","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1084\/jem.20081241","volume":"205","author":"SR Hinson","year":"2008","unstructured":"Hinson SR, Roemer SF, Lucchinetti CF et al (2008) Aquaporin-4-binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2. J Exp Med 205:2473\u20132481. https:\/\/doi.org\/10.1084\/jem.20081241","journal-title":"J Exp Med"},{"key":"9498_CR66","doi-asserted-by":"publisher","first-page":"45156","DOI":"10.1074\/jbc.M111.297275","volume":"286","author":"J Ratelade","year":"2011","unstructured":"Ratelade J, Bennett JL, Verkman AS (2011) Evidence against cellular internalization in vivo of NMO-IgG, aquaporin-4, and excitatory amino acid transporter 2 in neuromyelitis optica. J Biol Chem 286:45156\u201345164. https:\/\/doi.org\/10.1074\/jbc.M111.297275","journal-title":"J Biol Chem"},{"key":"9498_CR67","doi-asserted-by":"publisher","first-page":"5491","DOI":"10.1073\/pnas.1701960114","volume":"114","author":"SR Hinson","year":"2017","unstructured":"Hinson SR, Clift IC, Luo N et al (2017) Autoantibody-induced internalization of CNS AQP4 water channel and EAAT2 glutamate transporter requires astrocytic Fc receptor. Proc Natl Acad Sci 114:5491\u20135496. https:\/\/doi.org\/10.1073\/pnas.1701960114","journal-title":"Proc Natl Acad Sci"},{"key":"9498_CR68","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1002\/j.1460-2075.1987.tb02457.x","volume":"6","author":"KK Stanley","year":"1987","unstructured":"Stanley KK, Herz J (1987) Topological mapping of complement component C9 by recombinant DNA techniques suggests a novel mechanism for its insertion into target membranes. EMBO J 6:1951\u20131957","journal-title":"EMBO J"},{"key":"9498_CR69","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.1007\/s00415-017-8445-8","volume":"264","author":"D Whittam","year":"2017","unstructured":"Whittam D, Wilson M, Hamid S et al (2017) What\u2019s new in neuromyelitis optica? A short review for the clinical neurologist. J Neurol 264:2330\u20132344. https:\/\/doi.org\/10.1007\/s00415-017-8445-8","journal-title":"J Neurol"},{"key":"9498_CR70","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1007\/s00415-017-8596-7","volume":"264","author":"SHM Hamid","year":"2017","unstructured":"Hamid SHM, Whittam D, Mutch K et al (2017) What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patients. J Neurol 264:2088\u20132094. https:\/\/doi.org\/10.1007\/s00415-017-8596-7","journal-title":"J Neurol"},{"key":"9498_CR71","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1093\/brain\/awx276","volume":"140","author":"M Jurynczyk","year":"2017","unstructured":"Jurynczyk M, Messina S, Woodhall MR et al (2017) Clinical presentation and prognosis in MOG-antibody disease: a UK study. Brain 140:3128\u20133138. https:\/\/doi.org\/10.1093\/brain\/awx276","journal-title":"Brain"},{"key":"9498_CR72","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1172\/JCI28334","volume":"116","author":"E Bettelli","year":"2006","unstructured":"Bettelli E, Baeten D, J\u00e4ger A et al (2006) Myelin oligodendrocyte glycoprotein-specific T and B cells cooperate to induce a Devic-like disease in mice. J Clin Invest 116:2393\u20132402. https:\/\/doi.org\/10.1172\/JCI28334","journal-title":"J Clin Invest"},{"key":"9498_CR73","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1172\/JCI28330","volume":"116","author":"G Krishnamoorthy","year":"2006","unstructured":"Krishnamoorthy G, Lassmann H, Wekerle H, Holz A (2006) Spontaneous opticospinal encephalomyelitis in a double-transgenic mouse model of autoimmune T cell\/B cell cooperation. J Clin Invest 116:2385\u20132392. https:\/\/doi.org\/10.1172\/JCI28330","journal-title":"J Clin Invest"},{"key":"9498_CR74","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/2051-5960-2-35","volume":"2","author":"S Saadoun","year":"2014","unstructured":"Saadoun S, Waters P, Owens GP et al (2014) Neuromyelitis optica MOG-IgG causes reversible lesions in mouse brain. Acta Neuropathol Commun 2:35. https:\/\/doi.org\/10.1186\/2051-5960-2-35","journal-title":"Acta Neuropathol Commun"},{"key":"9498_CR75","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1111\/bpa.12084","volume":"23","author":"S Jarius","year":"2013","unstructured":"Jarius S, Wildemann B (2013) Aquaporin-4 antibodies (NMO-IgG) as a serological marker of neuromyelitis optica: a critical review of the literature. Brain Pathol 23:661\u2013683. https:\/\/doi.org\/10.1111\/bpa.12084","journal-title":"Brain Pathol"},{"key":"9498_CR76","doi-asserted-by":"crossref","first-page":"4577","DOI":"10.1074\/jbc.271.9.4577","volume":"271","author":"B Yang","year":"1996","unstructured":"Yang B, Brown D, Verkman AS (1996) The mercurial insensitive water channel (AQP-4) forms orthogonal arrays in stably transfected Chinese hamster ovary cells. J Biol Chem 271:4577\u20134580","journal-title":"J Biol Chem"},{"issue":"Pt 9","key":"9498_CR77","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1242\/jcs.108.9.2993","volume":"108","author":"A Frigeri","year":"1995","unstructured":"Frigeri A, Gropper MA, Umenishi F et al (1995) Localization of MIWC and GLIP water channel homologs in neuromuscular, epithelial and glandular tissues. J Cell Sci 108(Pt 9):2993\u20133002","journal-title":"J Cell Sci"},{"key":"9498_CR78","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1172\/JCI118463","volume":"97","author":"HG Folkesson","year":"1996","unstructured":"Folkesson HG, Matthay MA, Frigeri A, Verkman AS (1996) Transepithelial water permeability in microperfused distal airways. Evidence for channel-mediated water transport. J Clin Invest 97:664\u2013671. https:\/\/doi.org\/10.1172\/JCI118463","journal-title":"J Clin Invest"},{"key":"9498_CR79","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1681\/ASN.V105913","volume":"10","author":"I Saboli\u0107","year":"1999","unstructured":"Saboli\u0107 I, Herak-Kramberger CM, Breton S, Brown D (1999) Na\/K-ATPase in intercalated cells along the rat nephron revealed by antigen retrieval. J Am Soc Nephrol 10:913\u2013922","journal-title":"J Am Soc Nephrol"},{"key":"9498_CR80","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/00016489850183683","volume":"533","author":"Y Minami","year":"1998","unstructured":"Minami Y, Shimada S, Miyahara H et al (1998) Selective expression of mercurial-insensitive water channel (AQP-4) gene in Hensen and Claudius cells in the rat cochlea. Acta Otolaryngol Suppl 533:19\u201321","journal-title":"Acta Otolaryngol Suppl"},{"key":"9498_CR81","first-page":"573","volume":"43","author":"J Li","year":"2002","unstructured":"Li J, Patil RV, Verkman AS (2002) Mildly abnormal retinal function in transgenic mice without M\u00fcller cell aquaporin-4 water channels. Invest Ophthalmol Vis Sci 43:573\u2013579","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"9498_CR82","doi-asserted-by":"publisher","first-page":"267","DOI":"10.3109\/02713680903572525","volume":"35","author":"K J\u00e4ger","year":"2010","unstructured":"J\u00e4ger K, Reh D, Gebhardt M et al (2010) Expression profile of aquaporins in human nasolacrimal duct epithelium. Curr Eye Res 35:267\u2013273. https:\/\/doi.org\/10.3109\/02713680903572525","journal-title":"Curr Eye Res"},{"key":"9498_CR83","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1177\/1352458515571446","volume":"21","author":"S Saadoun","year":"2015","unstructured":"Saadoun S, Papadopoulos MC (2015) Role of membrane complement regulators in neuromyelitis optica. Mult Scler 21:1644\u20131654. https:\/\/doi.org\/10.1177\/1352458515571446","journal-title":"Mult Scler"},{"key":"9498_CR84","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1093\/brain\/aws109","volume":"135","author":"J Kitley","year":"2012","unstructured":"Kitley J, Leite MI, Nakashima I et al (2012) Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. Brain 135:1834\u20131849. https:\/\/doi.org\/10.1093\/brain\/aws109","journal-title":"Brain"},{"key":"9498_CR85","doi-asserted-by":"publisher","DOI":"10.1586\/14737175.2016.1150178","author":"J Kitley","year":"2016","unstructured":"Kitley J, Palace J (2016) Therapeutic options in neuromyelitis optica spectrum disorders. Expert Rev Neurother. https:\/\/doi.org\/10.1586\/14737175.2016.1150178","journal-title":"Expert Rev Neurother"},{"key":"9498_CR86","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1177\/1352458514525870","volume":"20","author":"L Elsone","year":"2014","unstructured":"Elsone L, Kitley J, Luppe S et al (2014) Long-term efficacy, tolerability and retention rate of azathioprine in 103 aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder patients: a multicentre retrospective observational study from the UK. Mult Scler 20:1533\u20131540. https:\/\/doi.org\/10.1177\/1352458514525870","journal-title":"Mult Scler"},{"key":"9498_CR87","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1177\/1352458516678474","volume":"23","author":"A Montcuquet","year":"2017","unstructured":"Montcuquet A, Collongues N, Papeix C et al (2017) Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders. Mult Scler 23:1377\u20131384. https:\/\/doi.org\/10.1177\/1352458516678474","journal-title":"Mult Scler"},{"key":"9498_CR88","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s12883-019-1261-2","volume":"19","author":"F Gao","year":"2019","unstructured":"Gao F, Chai B, Gu C et al (2019) Effectiveness of rituximab in neuromyelitis optica: a meta-analysis. BMC Neurol 19:36. https:\/\/doi.org\/10.1186\/s12883-019-1261-2","journal-title":"BMC Neurol"},{"key":"9498_CR89","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1001\/jamaneurol.2013.5699","volume":"71","author":"MA Mealy","year":"2014","unstructured":"Mealy MA, Wingerchuk DM, Palace J et al (2014) Comparison of relapse and treatment failure rates among patients with neuromyelitis optica. JAMA Neurol 71:324. https:\/\/doi.org\/10.1001\/jamaneurol.2013.5699","journal-title":"JAMA Neurol"},{"key":"9498_CR90","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/ncpneuro0376","volume":"3","author":"R Gold","year":"2007","unstructured":"Gold R, Stangel M, Dalakas MC (2007) Drug Insight: the use of intravenous immunoglobulin in neurology\u2014therapeutic considerations and practical issues. Nat Clin Pract Neurol 3:36\u201344. https:\/\/doi.org\/10.1038\/ncpneuro0376","journal-title":"Nat Clin Pract Neurol"},{"key":"9498_CR91","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1182\/blood-2003-05","volume":"103","author":"HU Lutz","year":"2004","unstructured":"Lutz HU, Stammler P, Bianchi V et al (2004) Intravenously applied IgG stimulates complement attenuation in a complement-dependent autoimmune disease at the amplifying C3 convertase level. Blood 103:465\u2013472. https:\/\/doi.org\/10.1182\/blood-2003-05","journal-title":"Blood"},{"key":"9498_CR92","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/nm836","volume":"9","author":"M Basta","year":"2003","unstructured":"Basta M, Van Goor F, Luccioli S et al (2003) F(ab)\u20192-mediated neutralization of C3a and C5a anaphylatoxins: a novel effector function of immunoglobulins. Nat Med 9:431\u2013438. https:\/\/doi.org\/10.1038\/nm836","journal-title":"Nat Med"},{"key":"9498_CR93","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.jneuroim.2015.03.021","volume":"282","author":"S Viswanathan","year":"2015","unstructured":"Viswanathan S, Wong AHY, Quek AML, Yuki N (2015) Intravenous immunoglobulin may reduce relapse frequency in neuromyelitis optica. J Neuroimmunol 282:92\u201396. https:\/\/doi.org\/10.1016\/j.jneuroim.2015.03.021","journal-title":"J Neuroimmunol"},{"key":"9498_CR94","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.nrl.2012.03.014","volume":"28","author":"MJ Magraner","year":"2013","unstructured":"Magraner MJ, Coret F, Casanova B (2013) Estudio del efecto del tratamiento con inmunoglobulinas por v\u00eda intravenosa en la neuromielitis \u00f3ptica. Neurolog\u00eda 28:65\u201372. https:\/\/doi.org\/10.1016\/j.nrl.2012.03.014","journal-title":"Neurolog\u00eda"},{"key":"9498_CR95","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s10875-012-9808-7","volume":"33","author":"DB Bichuetti","year":"2013","unstructured":"Bichuetti DB, Oliveira EML (2013) Comment on neuromyelitis optica: potential roles for intravenous immunoglobulin. J Clin Immunol 33:307. https:\/\/doi.org\/10.1007\/s10875-012-9808-7","journal-title":"J Clin Immunol"},{"key":"9498_CR96","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1177\/1352458513495938","volume":"20","author":"L Elsone","year":"2014","unstructured":"Elsone L, Panicker J, Mutch K et al (2014) Role of intravenous immunoglobulin in the treatment of acute relapses of neuromyelitis optica: experience in 10 patients. Mult Scler J 20:501\u2013504. https:\/\/doi.org\/10.1177\/1352458513495938","journal-title":"Mult Scler J"},{"key":"9498_CR97","doi-asserted-by":"publisher","DOI":"10.1136\/practneurol-2019-002336","author":"C Osman","year":"2019","unstructured":"Osman C, Jennings R, El-Ghariani K, Pinto A (2019) Plasma exchange in neurological disease. Pract Neurol Practneurol. https:\/\/doi.org\/10.1136\/practneurol-2019-002336","journal-title":"Pract Neurol Practneurol"},{"key":"9498_CR98","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2012\/787630","volume":"2012","author":"M Bonnan","year":"2012","unstructured":"Bonnan M, Cabre P (2012) Plasma exchange in severe attacks of neuromyelitis optica. Mult Scler Int 2012:1\u20139. https:\/\/doi.org\/10.1155\/2012\/787630","journal-title":"Mult Scler Int"},{"key":"9498_CR99","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1136\/jnnp-2017-316286","volume":"89","author":"M Bonnan","year":"2018","unstructured":"Bonnan M, Valentino R, Debeugny S et al (2018) Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders. J Neurol Neurosurg Psychiatry 89:346\u2013351. https:\/\/doi.org\/10.1136\/jnnp-2017-316286","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"9498_CR100","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1002\/ana.24554","volume":"79","author":"I Kleiter","year":"2016","unstructured":"Kleiter I, Gahlen A, Borisow N et al (2016) Neuromyelitis optica: evaluation of 871 attacks and 1,153 treatment courses. Ann Neurol 79:206\u2013216. https:\/\/doi.org\/10.1002\/ana.24554","journal-title":"Ann Neurol"},{"key":"9498_CR101","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1056\/NEJMoa061648","volume":"355","author":"P Hillmen","year":"2006","unstructured":"Hillmen P, Young NS, Schubert J et al (2006) The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 355:1233\u20131243. https:\/\/doi.org\/10.1056\/NEJMoa061648","journal-title":"N Engl J Med"},{"key":"9498_CR102","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/nrneph.2012.214","volume":"8","author":"J Zuber","year":"2012","unstructured":"Zuber J, Fakhouri F, Roumenina LT et al (2012) Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol 8:643\u2013657. https:\/\/doi.org\/10.1038\/nrneph.2012.214","journal-title":"Nat Rev Nephrol"},{"key":"9498_CR103","first-page":"1017","volume":"3","author":"M Kaplan","year":"2002","unstructured":"Kaplan M (2002) Eculizumab (Alexion). Curr Opin Investig Drugs 3:1017\u20131023","journal-title":"Curr Opin Investig Drugs"},{"key":"9498_CR104","unstructured":"Alexion (2018) Alexion Announces Successful Phase 3 PREVENT Study of Soliris\u00ae (Eculizumab) in Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD)| Alexion Pharmaceuticals, Inc. In: Press Release. https:\/\/news.alexionpharma.com\/press-release\/product-news\/alexion-announces-successful-phase-3-prevent-study-soliris-eculizumab-pat. Accessed 14 Mar 2019"},{"key":"9498_CR105","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1900866","author":"SJ Pittock","year":"2019","unstructured":"Pittock SJ, Berthele A, Fujihara K et al (2019) Eculizumab in aquaporin-4\u2014positive neuromyelitis optica spectrum disorder. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa1900866","journal-title":"N Engl J Med"},{"key":"9498_CR106","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12974-019-1448-x","volume":"16","author":"L Tradtrantip","year":"2019","unstructured":"Tradtrantip L, Duan T, Yeaman MR, Verkman AS (2019) CD55 upregulation in astrocytes by statins as potential therapy for AQP4-IgG seropositive neuromyelitis optica. J Neuroinflammation 16:57. https:\/\/doi.org\/10.1186\/s12974-019-1448-x","journal-title":"J Neuroinflammation"},{"key":"9498_CR107","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1016\/S0140-6736(00)05186-2","volume":"357","author":"A Vincent","year":"2001","unstructured":"Vincent A, Palace J, Hilton-Jones D (2001) Myasthenia gravis. Lancet 357:2122\u20132128. https:\/\/doi.org\/10.1016\/S0140-6736(00)05186-2","journal-title":"Lancet"},{"key":"9498_CR108","doi-asserted-by":"publisher","first-page":"2843","DOI":"10.1172\/JCI29894","volume":"116","author":"BM Conti-Fine","year":"2006","unstructured":"Conti-Fine BM, Milani M, Kaminski HJ (2006) Myasthenia gravis: past, present, and future. J Clin Invest 116:2843\u20132854. https:\/\/doi.org\/10.1172\/JCI29894","journal-title":"J Clin Invest"},{"key":"9498_CR109","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2015.02.025","author":"LL Kusner","year":"2015","unstructured":"Kusner LL, Losen M, Vincent A et al (2015) Guidelines for pre-clinical assessment of the acetylcholine receptor-specific passive transfer myasthenia gravis model-recommendations for methods and experimental designs. Exp Neurol. https:\/\/doi.org\/10.1016\/j.expneurol.2015.02.025","journal-title":"Exp Neurol"},{"key":"9498_CR110","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1126\/science.180.4088.871","volume":"180","author":"J Patrick","year":"1973","unstructured":"Patrick J, Lindstrom J (1973) Autoimmune response to acetylcholine receptor. Science 180:871\u2013872","journal-title":"Science"},{"key":"9498_CR111","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJM197701202960301","volume":"296","author":"KV Toyka","year":"1977","unstructured":"Toyka KV, Drachman DB, Griffin DE et al (1977) Myasthenia Gravis. N Engl J Med 296:125\u2013131. https:\/\/doi.org\/10.1056\/NEJM197701202960301","journal-title":"N Engl J Med"},{"key":"9498_CR112","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1212\/WNL.28.3.266","volume":"28","author":"J Newsom-Davis","year":"1978","unstructured":"Newsom-Davis J, Pinching AJ, Vincent A, Wilson SG (1978) Function of circulating antibody to acetylcholine receptor in myasthenia gravis: investigation by plasma exchange. Neurology 28:266\u2013272","journal-title":"Neurology"},{"key":"9498_CR113","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1212\/WNL.26.11.1054","volume":"26","author":"JM Lindstrom","year":"1976","unstructured":"Lindstrom JM, Seybold ME, Lennon VA et al (1976) Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology 26:1054\u20131059","journal-title":"Neurology"},{"key":"9498_CR114","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/285238a0","volume":"285","author":"VA Lennon","year":"1980","unstructured":"Lennon VA, Lambert EH (1980) Myasthenia gravis induced by monoclonal antibodies to acetylcholine receptors. Nature 285:238\u2013240","journal-title":"Nature"},{"key":"9498_CR115","first-page":"82","volume":"67","author":"A R\u00f8dgaard","year":"1987","unstructured":"R\u00f8dgaard A, Nielsen FC, Djurup R et al (1987) Acetylcholine receptor antibody in myasthenia gravis: predominance of IgG subclasses 1 and 3. Clin Exp Immunol 67:82\u201388","journal-title":"Clin Exp Immunol"},{"key":"9498_CR116","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1073\/pnas.74.7.3090","volume":"74","author":"S Heinemann","year":"1977","unstructured":"Heinemann S, Bevan S, Kullberg R et al (1977) Modulation of acetylcholine receptor by antibody against the receptor. Proc Natl Acad Sci USA 74:3090\u20133094","journal-title":"Proc Natl Acad Sci USA"},{"key":"9498_CR117","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJM197805182982004","volume":"298","author":"DB Drachman","year":"1978","unstructured":"Drachman DB, Angus CW, Adams RN et al (1978) Myasthenic antibodies cross-link acetylcholine receptors to accelerate degradation. N Engl J Med 298:1116\u20131122. https:\/\/doi.org\/10.1056\/NEJM197805182982004","journal-title":"N Engl J Med"},{"key":"9498_CR118","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1002\/eji.1830220939","volume":"22","author":"H Loutrari","year":"1992","unstructured":"Loutrari H, Kokla A, Tzartos SJ (1992) Passive transfer of experimental myasthenia gravis via antigenic modulation of acetylcholine receptor. Eur J Immunol 22:2449\u20132452. https:\/\/doi.org\/10.1002\/eji.1830220939","journal-title":"Eur J Immunol"},{"key":"9498_CR119","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1196\/annals.1405.034","volume":"1132","author":"M Losen","year":"2008","unstructured":"Losen M, Mart\u00ednez-Mart\u00ednez P, Phernambucq M et al (2008) Treatment of myasthenia gravis by preventing acetylcholine receptor modulation. Ann N Y Acad Sci 1132:174\u2013179. https:\/\/doi.org\/10.1196\/annals.1405.034","journal-title":"Ann N Y Acad Sci"},{"key":"9498_CR120","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1126\/science.186.4158.55","volume":"186","author":"RR Almon","year":"1974","unstructured":"Almon RR, Andrew CG, Appel SH (1974) Serum globulin in myasthenia gravis: inhibition of alpha-bungarotoxin binding to acetylcholine receptors. Science 186:55\u201357","journal-title":"Science"},{"key":"9498_CR121","doi-asserted-by":"crossref","first-page":"4089","DOI":"10.1073\/pnas.80.13.4089","volume":"80","author":"CM Gomez","year":"1983","unstructured":"Gomez CM, Richman DP (1983) Anti-acetylcholine receptor antibodies directed against the alpha-bungarotoxin binding site induce a unique form of experimental myasthenia. Proc Natl Acad Sci USA 80:4089\u20134093","journal-title":"Proc Natl Acad Sci USA"},{"key":"9498_CR122","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1093\/clinchem\/39.10.2053","volume":"39","author":"H Hara","year":"1993","unstructured":"Hara H, Hayashi K, Ohta K et al (1993) Detection and characterization of blocking-type anti-acetylcholine receptor antibodies in sera from patients with myasthenia gravis. Clin Chem 39:2053\u20132057","journal-title":"Clin Chem"},{"key":"9498_CR123","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/0165-5728(88)90043-4","volume":"19","author":"B Lang","year":"1988","unstructured":"Lang B, Richardson G, Rees J et al (1988) Plasma from myasthenia gravis patients reduces acetylcholine receptor agonist-induced Na+\u2009flux into TE671 cell line. J Neuroimmunol 19:141\u2013148","journal-title":"J Neuroimmunol"},{"key":"9498_CR124","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1056\/NEJMra1602678","volume":"375","author":"NE Gilhus","year":"2016","unstructured":"Gilhus NE (2016) Myasthenia Gravis. N Engl J Med 375:2570\u20132581. https:\/\/doi.org\/10.1056\/NEJMra1602678","journal-title":"N Engl J Med"},{"key":"9498_CR125","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/85520","volume":"7","author":"W Hoch","year":"2001","unstructured":"Hoch W, McConville J, Helms S et al (2001) Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 7:365\u2013368. https:\/\/doi.org\/10.1038\/85520","journal-title":"Nat Med"},{"key":"9498_CR126","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1111\/nyas.13592","volume":"1413","author":"A Vincent","year":"2018","unstructured":"Vincent A, Huda S, Cao M et al (2018) Serological and experimental studies in different forms of myasthenia gravis. Ann N Y Acad Sci 1413:143\u2013153. https:\/\/doi.org\/10.1111\/nyas.13592","journal-title":"Ann N Y Acad Sci"},{"key":"9498_CR127","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/nyas.13518","volume":"1412","author":"A Evoli","year":"2018","unstructured":"Evoli A, Alboini PE, Damato V et al (2018) Myasthenia gravis with antibodies to MuSK: an update. Ann N Y Acad Sci 1412:82\u201389. https:\/\/doi.org\/10.1111\/nyas.13518","journal-title":"Ann N Y Acad Sci"},{"key":"9498_CR128","doi-asserted-by":"publisher","first-page":"7356","DOI":"10.1523\/JNEUROSCI.0397-12.2012","volume":"32","author":"J-Y Park","year":"2012","unstructured":"Park J-Y, Ikeda H, Ikenaga T, Ono F (2012) Acetylcholine receptors enable the transport of rapsyn from the Golgi complex to the plasma membrane. J Neurosci 32:7356\u20137363. https:\/\/doi.org\/10.1523\/JNEUROSCI.0397-12.2012","journal-title":"J Neurosci"},{"key":"9498_CR129","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1093\/brain\/aws025","volume":"135","author":"R Klooster","year":"2012","unstructured":"Klooster R, Plomp JJ, Huijbers MG et al (2012) Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice. Brain 135:1081\u20131101. https:\/\/doi.org\/10.1093\/brain\/aws025","journal-title":"Brain"},{"key":"9498_CR130","doi-asserted-by":"publisher","first-page":"20783","DOI":"10.1073\/pnas.1313944110","volume":"110","author":"MG Huijbers","year":"2013","unstructured":"Huijbers MG, Zhang W, Klooster R et al (2013) MuSK IgG4 autoantibodies cause myasthenia gravis by inhibiting binding between MuSK and Lrp4. Proc Natl Acad Sci 110:20783\u201320788. https:\/\/doi.org\/10.1073\/pnas.1313944110","journal-title":"Proc Natl Acad Sci"},{"key":"9498_CR131","first-page":"331","volume":"66","author":"CL Williams","year":"1992","unstructured":"Williams CL, Hay JE, Huiatt TW, Lennon VA (1992) Paraneoplastic IgG striational autoantibodies produced by clonal thymic B cells and in serum of patients with myasthenia gravis and thymoma react with titin. Lab Invest 66:331\u2013336","journal-title":"Lab Invest"},{"key":"9498_CR132","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1111\/j.1468-1331.1997.tb00318.x","volume":"4","author":"GO Skeie","year":"1997","unstructured":"Skeie GO, Aarli JA, Matre R et al (1997) Titin antibody positive myasthenia gravis patients have a cellular immune response against the main immunogenic region of titin. Eur J Neurol 4:131\u2013137. https:\/\/doi.org\/10.1111\/j.1468-1331.1997.tb00318.x","journal-title":"Eur J Neurol"},{"key":"9498_CR133","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1002\/ana.410320419","volume":"32","author":"\u00c5SE Mygland","year":"1992","unstructured":"Mygland \u00c5SE, Tysnes O-B, Aarli JA et al (1992) Ryanodine receptor autoantibodies in myasthenia gravis patients with a thymoma. Ann Neurol 32:589\u2013591. https:\/\/doi.org\/10.1002\/ana.410320419","journal-title":"Ann Neurol"},{"key":"9498_CR134","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/(SICI)1097-4598(199803)21:3<329::AID-MUS6>3.0.CO;2-C","volume":"21","author":"GO Skeie","year":"1998","unstructured":"Skeie GO, Lunde PK, Sejersted OM et al (1998) Myasthenia gravis sera containing antiryanodine receptor antibodies inhibit binding of [3H]-ryanodine to sarcoplasmic reticulum. Muscle Nerve 21:329\u2013335","journal-title":"Muscle Nerve"},{"key":"9498_CR135","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0165-5728(00)00394-5","volume":"111","author":"F Romi","year":"2000","unstructured":"Romi F, Skeie GO, Vedeler C et al (2000) Complement activation by titin and ryanodine receptor autoantibodies in myasthenia gravis. A study of IgG subclasses and clinical correlations. J Neuroimmunol 111:169\u2013176","journal-title":"J Neuroimmunol"},{"key":"9498_CR136","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/j.1600-0404.2006.00608.x","volume":"113","author":"GO Skeie","year":"2006","unstructured":"Skeie GO, Aarli JA, Gilhus NE (2006) Titin and ryanodine receptor antibodies in myasthenia gravis. Acta Neurol Scand 113:19\u201323. https:\/\/doi.org\/10.1111\/j.1600-0404.2006.00608.x","journal-title":"Acta Neurol Scand"},{"key":"9498_CR137","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jaut.2013.12.004","volume":"52","author":"P Zisimopoulou","year":"2014","unstructured":"Zisimopoulou P, Evangelakou P, Tzartos J et al (2014) A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis. J Autoimmun 52:139\u2013145. https:\/\/doi.org\/10.1016\/j.jaut.2013.12.004","journal-title":"J Autoimmun"},{"key":"9498_CR138","doi-asserted-by":"publisher","first-page":"e91816","DOI":"10.1371\/journal.pone.0091816","volume":"9","author":"B Zhang","year":"2014","unstructured":"Zhang B, Shen C, Bealmear B et al (2014) Autoantibodies to agrin in myasthenia gravis patients. PLoS One 9:e91816. https:\/\/doi.org\/10.1371\/journal.pone.0091816","journal-title":"PLoS One"},{"key":"9498_CR139","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/j.autrev.2014.08.039","volume":"13","author":"E Gallardo","year":"2014","unstructured":"Gallardo E, Mart\u00ednez-Hern\u00e1ndez E, Titulaer MJ et al (2014) Cortactin autoantibodies in myasthenia gravis. Autoimmun Rev 13:1003\u20131007. https:\/\/doi.org\/10.1016\/j.autrev.2014.08.039","journal-title":"Autoimmun Rev"},{"key":"9498_CR140","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1001\/jamaneurol.2016.2032","volume":"73","author":"E Cort\u00e9s-Vicente","year":"2016","unstructured":"Cort\u00e9s-Vicente E, Gallardo E, Mart\u00ednez M\u00c1 et al (2016) Clinical characteristics of patients with double-seronegative myasthenia gravis and antibodies to cortactin. JAMA Neurol 73:1099. https:\/\/doi.org\/10.1001\/jamaneurol.2016.2032","journal-title":"JAMA Neurol"},{"key":"9498_CR141","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1111\/nyas.13502","volume":"1412","author":"I Illa","year":"2018","unstructured":"Illa I, Cort\u00e9s-Vicente E, Mart\u00ednez M\u00c1, Gallardo E (2018) Diagnostic utility of cortactin antibodies in myasthenia gravis. Ann N Y Acad Sci 1412:90\u201394. https:\/\/doi.org\/10.1111\/nyas.13502","journal-title":"Ann N Y Acad Sci"},{"key":"9498_CR142","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1084\/jem.144.3.739","volume":"144","author":"JM Lindstrom","year":"1976","unstructured":"Lindstrom JM, Engel AG, Seybold ME et al (1976) Pathological mechanisms in experimental autoimmune myasthenia gravis. II. Passive transfer of experimental autoimmune myasthenia gravis in rats with anti-acetylcholine recepotr antibodies. J Exp Med 144:739\u2013753","journal-title":"J Exp Med"},{"key":"9498_CR143","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3181\/00379727-105-26050","volume":"105","author":"WL Nastuk","year":"1960","unstructured":"Nastuk WL, Plescia OJ, Osserman KE (1960) Changes in serum complement activity in patients with myasthenia gravis. Proc Soc Exp Biol Med 105:177\u2013184","journal-title":"Proc Soc Exp Biol Med"},{"key":"9498_CR144","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/ana.410010403","volume":"1","author":"AG Engel","year":"1977","unstructured":"Engel AG, Lambert EH, Gomez MR (1977) A new myasthenic syndrome with end-plate acetylcholinesterase deficiency, small nerve terminals, and reduced acetylcholine release. Ann Neurol 1:315\u2013330. https:\/\/doi.org\/10.1002\/ana.410010403","journal-title":"Ann Neurol"},{"key":"9498_CR145","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/00005072-197803000-00008","volume":"37","author":"K Sahashi","year":"1978","unstructured":"Sahashi K, Engel AG, Linstrom JM et al (1978) Ultrastructural localization of immune complexes (IgG and C3) at the end-plate in experimental autoimmune myasthenia gravis. J Neuropathol Exp Neurol 37:212\u2013223","journal-title":"J Neuropathol Exp Neurol"},{"key":"9498_CR146","first-page":"78","volume":"2","author":"A Fazekas","year":"1986","unstructured":"Fazekas A, Komoly S, Bozsik B, Szobor A (1986) Myasthenia gravis: demonstration of membrane attack complex in muscle end-plates. - PubMed - NCBI. Clin Neuropathol 2:78\u201383","journal-title":"Clin Neuropathol"},{"key":"9498_CR147","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1749-6632.1987.tb51301.x","volume":"505","author":"AG Engel","year":"1987","unstructured":"Engel AG, Arahata K (1987) The membrane attack complex of complement at the endplate in myasthenia gravis. Ann N Y Acad Sci 505:326\u2013332","journal-title":"Ann N Y Acad Sci"},{"key":"9498_CR148","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/S0140-6736(76)92644-1","volume":"2","author":"P Casali","year":"1976","unstructured":"Casali P, Borzini P, Zanussi C (1976) Letter: immune complexes in myasthenia gravis. Lancet (London, England) 2:378","journal-title":"Lancet (London, England)"},{"key":"9498_CR149","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/0303-8467(93)90103-N","volume":"95","author":"RJ Barohn","year":"1993","unstructured":"Barohn RJ, Brey RL (1993) Soluble terminal complement components in human myasthenia gravis. Clin Neurol Neurosurg 95:285\u2013290","journal-title":"Clin Neurol Neurosurg"},{"key":"9498_CR150","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/j.1600-0404.1991.tb03968.x","volume":"83","author":"N Kamolvarin","year":"1991","unstructured":"Kamolvarin N, Hemachudha T, Ongpipattanakul B et al (1991) Plasma C3c in immune-mediated neurological diseases: a preliminary report. Acta Neurol Scand 83:382\u2013387","journal-title":"Acta Neurol Scand"},{"key":"9498_CR151","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0165-5728(96)00133-6","volume":"71","author":"M Basta","year":"1996","unstructured":"Basta M, Illa I, Dalakas MC (1996) Increased in vitro uptake of the complement C3b in the serum of patients with Guillain-Barr\u00e9 syndrome, myasthenia gravis and dermatomyositis. J Neuroimmunol 71:227\u2013229","journal-title":"J Neuroimmunol"},{"key":"9498_CR152","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.jneuroim.2004.08.002","volume":"158","author":"F Romi","year":"2005","unstructured":"Romi F, Kristoffersen EK, Aarli JA, Gilhus NE (2005) The role of complement in myasthenia gravis: serological evidence of complement consumption in vivo. J Neuroimmunol 158:191\u2013194. https:\/\/doi.org\/10.1016\/j.jneuroim.2004.08.002","journal-title":"J Neuroimmunol"},{"key":"9498_CR153","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1084\/jem.147.4.973","volume":"147","author":"VA Lennon","year":"1978","unstructured":"Lennon VA, Seybold ME, Lindstrom JM et al (1978) Role of complement in the pathogenesis of experimental autoimmune myasthenia gravis. J Exp Med 147:973\u2013983","journal-title":"J Exp Med"},{"key":"9498_CR154","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.4049\/jimmunol.140.8.2589","volume":"140","author":"P Christadoss","year":"1988","unstructured":"Christadoss P (1988) C5 gene influences the development of murine myasthenia gravis. J Immunol 140:2589\u20132592","journal-title":"J Immunol"},{"key":"9498_CR155","doi-asserted-by":"crossref","first-page":"3847","DOI":"10.4049\/jimmunol.171.7.3847","volume":"171","author":"E T\u00fcz\u00fcn","year":"2003","unstructured":"T\u00fcz\u00fcn E, Scott BG, Goluszko E et al (2003) Genetic evidence for involvement of classical complement pathway in induction of experimental autoimmune myasthenia gravis. J Immunol 171:3847\u20133854","journal-title":"J Immunol"},{"key":"9498_CR156","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.4049\/jimmunol.142.8.2654","volume":"142","author":"G Biesecker","year":"1989","unstructured":"Biesecker G, Gomez CM (1989) Inhibition of acute passive transfer experimental autoimmune myasthenia gravis with Fab antibody to complement C6. J Immunol 142:2654\u20132659","journal-title":"J Immunol"},{"key":"9498_CR157","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1111\/j.1365-2249.2006.03198.x","volume":"146","author":"J Chamberlain-Banoub","year":"2006","unstructured":"Chamberlain-Banoub J, Neal JW, Mizuno M et al (2006) Complement membrane attack is required for endplate damage and clinical disease in passive experimental myasthenia gravis in Lewis rats. Clin Exp Immunol 146:278\u2013286. https:\/\/doi.org\/10.1111\/j.1365-2249.2006.03198.x","journal-title":"Clin Exp Immunol"},{"key":"9498_CR158","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1172\/JCI16086","volume":"110","author":"F Lin","year":"2002","unstructured":"Lin F, Kaminski HJ, Conti-Fine BM et al (2002) Markedly enhanced susceptibility to experimental autoimmune myasthenia gravis in the absence of decay-accelerating factor protection. J Clin Invest 110:1269\u20131274. https:\/\/doi.org\/10.1172\/JCI16086","journal-title":"J Clin Invest"},{"key":"9498_CR159","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1111\/j.1365-2249.2006.03205.x","volume":"146","author":"BP Morgan","year":"2006","unstructured":"Morgan BP, Chamberlain-Banoub J, Neal JW et al (2006) The membrane attack pathway of complement drives pathology in passively induced experimental autoimmune myasthenia gravis in mice. Clin Exp Immunol 146:294\u2013302. https:\/\/doi.org\/10.1111\/j.1365-2249.2006.03205.x","journal-title":"Clin Exp Immunol"},{"key":"9498_CR160","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1002\/mus.23448","volume":"47","author":"LL Kusner","year":"2013","unstructured":"Kusner LL, Halperin JA, Kaminski HJ (2013) Cell surface complement regulators moderate experimental myasthenia gravis pathology. Muscle Nerve 47:33\u201340. https:\/\/doi.org\/10.1002\/mus.23448","journal-title":"Muscle Nerve"},{"key":"9498_CR161","first-page":"E63","volume":"5","author":"SS Asghar","year":"2000","unstructured":"Asghar SS, Pasch MC (2000) Therapeutic inhibition of the complement system. Y2K update. Front Biosci 5:E63\u2013E81","journal-title":"Front Biosci"},{"key":"9498_CR162","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1002\/mus.24057","volume":"49","author":"LL Kusner","year":"2014","unstructured":"Kusner LL, Satija N, Cheng G, Kaminski HJ (2014) Targeting therapy to the neuromuscular junction: proof of concept. Muscle Nerve 49:749\u2013756. https:\/\/doi.org\/10.1002\/mus.24057","journal-title":"Muscle Nerve"},{"key":"9498_CR163","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0165-5728(96)00144-0","volume":"71","author":"SJ Piddlesden","year":"1996","unstructured":"Piddlesden SJ, Jiang S, Levin JL et al (1996) Soluble complement receptor 1 (sCR166) protects against experimental autoimmune myasthenia gravis. J Neuroimmunol 71:173\u2013177","journal-title":"J Neuroimmunol"},{"key":"9498_CR164","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.molimm.2007.06.144","volume":"45","author":"NJ Hepburn","year":"2008","unstructured":"Hepburn NJ, Chamberlain-Banoub JL, Williams AS et al (2008) Prevention of experimental autoimmune myasthenia gravis by rat Crry-Ig: a model agent for long-term complement inhibition in vivo. Mol Immunol 45:395\u2013405. https:\/\/doi.org\/10.1016\/j.molimm.2007.06.144","journal-title":"Mol Immunol"},{"key":"9498_CR165","doi-asserted-by":"publisher","first-page":"8292","DOI":"10.1074\/jbc.M609858200","volume":"282","author":"NJ Hepburn","year":"2007","unstructured":"Hepburn NJ, Williams AS, Nunn MA et al (2007) In Vivo Characterization and Therapeutic Efficacy of a C5-specific Inhibitor from the Soft Tick Ornithodoros moubata. J Biol Chem 282:8292\u20138299. https:\/\/doi.org\/10.1074\/jbc.M609858200","journal-title":"J Biol Chem"},{"key":"9498_CR166","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/ana.21536","volume":"65","author":"J Soltys","year":"2009","unstructured":"Soltys J, Kusner LL, Young A et al (2009) Novel complement inhibitor limits severity of experimentally myasthenia gravis. Ann Neurol 65:67\u201375. https:\/\/doi.org\/10.1002\/ana.21536","journal-title":"Ann Neurol"},{"key":"9498_CR167","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.jneuroim.2006.10.014","volume":"182","author":"E T\u00fcz\u00fcn","year":"2007","unstructured":"T\u00fcz\u00fcn E, Li J, Saini SS et al (2007) Pros and cons of treating murine myasthenia gravis with anti-C1q antibody. J Neuroimmunol 182:167\u2013176. https:\/\/doi.org\/10.1016\/j.jneuroim.2006.10.014","journal-title":"J Neuroimmunol"},{"key":"9498_CR168","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.jaut.2013.01.003","volume":"42","author":"R Huda","year":"2013","unstructured":"Huda R, T\u00fcz\u00fcn E, Christadoss P (2013) Complement C2 siRNA mediated therapy of myasthenia gravis in mice. J Autoimmun 42:94\u2013104. https:\/\/doi.org\/10.1016\/j.jaut.2013.01.003","journal-title":"J Autoimmun"},{"key":"9498_CR169","doi-asserted-by":"crossref","first-page":"8562","DOI":"10.4049\/jimmunol.179.12.8562","volume":"179","author":"Y Zhou","year":"2007","unstructured":"Zhou Y, Gong B, Lin F et al (2007) Anti-C5 antibody treatment ameliorates weakness in experimentally acquired myasthenia gravis. J Immunol 179:8562\u20138567","journal-title":"J Immunol"},{"key":"9498_CR170","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1093\/brain\/awg223","volume":"126","author":"A Evoli","year":"2003","unstructured":"Evoli A, Tonali PA, Padua L et al (2003) Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain 126:2304\u20132311. https:\/\/doi.org\/10.1093\/brain\/awg223","journal-title":"Brain"},{"key":"9498_CR171","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1002\/ana.410410615","volume":"41","author":"P Gajdos","year":"1997","unstructured":"Gajdos P, Chevret S, Clair B et al (1997) Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Ann Neurol 41:789\u2013796. https:\/\/doi.org\/10.1002\/ana.410410615","journal-title":"Ann Neurol"},{"key":"9498_CR172","doi-asserted-by":"publisher","first-page":"CD002277","DOI":"10.1002\/14651858.CD002277.pub4","volume":"12","author":"P Gajdos","year":"2012","unstructured":"Gajdos P, Chevret S, Toyka KV (2012) Intravenous immunoglobulin for myasthenia gravis. Cochrane Database Syst Rev 12:CD002277. https:\/\/doi.org\/10.1002\/14651858.CD002277.pub4","journal-title":"Cochrane Database Syst Rev"},{"key":"9498_CR173","first-page":"265","volume":"88","author":"PC Dau","year":"1982","unstructured":"Dau PC (1982) Plasmapheresis in myasthenia gravis. Prog Clin Biol Res 88:265\u2013285","journal-title":"Prog Clin Biol Res"},{"key":"9498_CR174","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1001\/archneur.1981.00510080040003","volume":"38","author":"P Kornfeld","year":"1981","unstructured":"Kornfeld P, Ambinder EP, Mittag T et al (1981) Plasmapheresis in refractory generalized myasthenia gravis. Arch Neurol 38:478\u2013481. https:\/\/doi.org\/10.1001\/archneur.1981.00510080040003","journal-title":"Arch Neurol"},{"key":"9498_CR175","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1136\/thx.50.10.1080","volume":"50","author":"P Goti","year":"1995","unstructured":"Goti P, Spinelli A, Marconi G et al (1995) Comparative effects of plasma exchange and pyridostigmine on respiratory muscle strength and breathing pattern in patients with myasthenia gravis. Thorax 50:1080\u20131086. https:\/\/doi.org\/10.1136\/thx.50.10.1080","journal-title":"Thorax"},{"key":"9498_CR176","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s11748-005-1001-y","volume":"53","author":"T Nagayasu","year":"2005","unstructured":"Nagayasu T, Yamayoshi T, Matsumoto K et al (2005) Beneficial effects of plasmapheresis before thymectomy on the outcome in myasthenia gravis. Jpn J Thorac Cardiovasc Surg 53:2\u20137. https:\/\/doi.org\/10.1007\/s11748-005-1001-y","journal-title":"Jpn J Thorac Cardiovasc Surg"},{"key":"9498_CR177","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1212\/WNL.50.6.1778","volume":"50","author":"J Palace","year":"1998","unstructured":"Palace J, Newsom-Davis J, Lecky B (1998) A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group. Neurology 50:1778\u20131783","journal-title":"Neurology"},{"key":"9498_CR178","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1212\/01.wnl.0000312374.95186.cc","volume":"71","author":"DB Sanders","year":"2008","unstructured":"Sanders DB, Hart IK, Mantegazza R et al (2008) An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis. Neurology 71:400\u2013406. https:\/\/doi.org\/10.1212\/01.wnl.0000312374.95186.cc","journal-title":"Neurology"},{"key":"9498_CR179","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1212\/WNL.0000000000002795","volume":"87","author":"M Pasnoor","year":"2016","unstructured":"Pasnoor M, He J, Herbelin L et al (2016) A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis. Neurology 87:57\u201364. https:\/\/doi.org\/10.1212\/WNL.0000000000002795","journal-title":"Neurology"},{"key":"9498_CR180","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/1471-2377-11-97","volume":"11","author":"JM Heckmann","year":"2011","unstructured":"Heckmann JM, Rawoot A, Bateman K et al (2011) A single-blinded trial of methotrexate versus azathioprine as steroid-sparing agents in generalized myasthenia gravis. BMC Neurol 11:97. https:\/\/doi.org\/10.1186\/1471-2377-11-97","journal-title":"BMC Neurol"},{"key":"9498_CR181","doi-asserted-by":"publisher","first-page":"417.2-417","DOI":"10.1212\/WNL.0000000000003547","volume":"88","author":"JM Heckmann","year":"2017","unstructured":"Heckmann JM, Bateman K (2017) Letter re: a randomized controlled trial of methotrexate for patients with generalized myasthenia gravis. Neurology 88:417.2-417. https:\/\/doi.org\/10.1212\/WNL.0000000000003547","journal-title":"Neurology"},{"key":"9498_CR182","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/mus.25597","volume":"56","author":"R Tandan","year":"2017","unstructured":"Tandan R, Hehir MK, Waheed W, Howard DB (2017) Rituximab treatment of myasthenia gravis: a systematic review. Muscle Nerve 56:185\u2013196. https:\/\/doi.org\/10.1002\/mus.25597","journal-title":"Muscle Nerve"},{"key":"9498_CR183","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1056\/NEJMc1611704","volume":"375","author":"GI Wolfe","year":"2016","unstructured":"Wolfe GI, Kaminski HJ, Cutter GR (2016) Randomized trial of thymectomy in myasthenia gravis. N Engl J Med 375:2005\u20132007. https:\/\/doi.org\/10.1056\/NEJMc1611704","journal-title":"N Engl J Med"},{"key":"9498_CR184","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1136\/practneurol-2015-001126","volume":"15","author":"J Sussman","year":"2015","unstructured":"Sussman J, Farrugia ME, Maddison P et al (2015) Myasthenia gravis: association of British Neurologists\u2019 management guidelines. Pract Neurol 15:199\u2013206. https:\/\/doi.org\/10.1136\/practneurol-2015-001126","journal-title":"Pract Neurol"},{"key":"9498_CR185","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1182\/blood-2007-06-094136","volume":"111","author":"RA Brodsky","year":"2008","unstructured":"Brodsky RA, Young NS, Antonioli E et al (2008) Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood 111:1840\u20131847. https:\/\/doi.org\/10.1182\/blood-2007-06-094136","journal-title":"Blood"},{"key":"9498_CR186","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1111\/all.12658","volume":"70","author":"BL Zuraw","year":"2015","unstructured":"Zuraw BL, Cicardi M, Longhurst HJ et al (2015) Phase II study results of a replacement therapy for hereditary angioedema with subcutaneous C1-inhibitor concentrate. Allergy 70:1319\u20131328. https:\/\/doi.org\/10.1111\/all.12658","journal-title":"Allergy"},{"key":"9498_CR187","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.iac.2017.03.003","volume":"37","author":"M Chen","year":"2017","unstructured":"Chen M, Riedl MA (2017) Emerging therapies in hereditary angioedema. Immunol Allergy Clin N Am 37:585\u2013595. https:\/\/doi.org\/10.1016\/j.iac.2017.03.003","journal-title":"Immunol Allergy Clin N Am"},{"key":"9498_CR188","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","volume":"16","author":"JF Howard","year":"2017","unstructured":"Howard JF, Utsugisawa K, Benatar M et al (2017) Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol 16:976\u2013986. https:\/\/doi.org\/10.1016\/S1474-4422(17)30369-1","journal-title":"Lancet Neurol"},{"key":"9498_CR189","doi-asserted-by":"publisher","first-page":"e0195909","DOI":"10.1371\/journal.pone.0195909","volume":"13","author":"D Sheridan","year":"2018","unstructured":"Sheridan D, Yu Z-X, Zhang Y et al (2018) Design and preclinical characterization of ALXN1210: a novel anti-C5 antibody with extended duration of action. PLoS One 13:e0195909. https:\/\/doi.org\/10.1371\/journal.pone.0195909","journal-title":"PLoS One"},{"key":"9498_CR190","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s40265-019-01068-2","volume":"79","author":"K McKeage","year":"2019","unstructured":"McKeage K (2019) Ravulizumab: first global approval. Drugs 79:347\u2013352. https:\/\/doi.org\/10.1007\/s40265-019-01068-2","journal-title":"Drugs"}],"updated-by":[{"DOI":"10.1007\/s00415-021-10896-w","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,11,15]],"date-time":"2021-11-15T00:00:00Z","timestamp":1636934400000}},{"DOI":"10.1007\/s00415-019-09568-7","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2019,10,17]],"date-time":"2019-10-17T00:00:00Z","timestamp":1571270400000}}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-019-09498-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-019-09498-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-019-09498-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T20:02:13Z","timestamp":1695153733000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-019-09498-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,3]]},"references-count":190,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["9498"],"URL":"https:\/\/doi.org\/10.1007\/s00415-019-09498-4","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s00415-021-10896-w","asserted-by":"object"},{"id-type":"doi","id":"10.1007\/s00415-019-09568-7","asserted-by":"object"}]},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,3]]},"assertion":[{"value":"31 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2021","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00415-021-10896-w","URL":"https:\/\/doi.org\/10.1007\/s00415-021-10896-w","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2019","order":9,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":10,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00415-019-09568-7","URL":"https:\/\/doi.org\/10.1007\/s00415-019-09568-7","order":12,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"AJ: Principal Investigator for the ECU301 and ECU302 trials on Eculizumab in neuromyelitis optica in the UK. AJ has also received research grants from Alexion Pharmaceuticals, Biogen Idec and speaker fees from Biogeb, Chugai, Sanofi-Genzyme and Terumo-BCT. MM: Adboard consulting for Alexion Pharmaceuticals. JC, SH, DH and BPM have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This is a review article and does not involve any animal or human research.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards statement"}}]}}